Opinion: Writer sees biotechs entering 2005 with "good momentum"

12/30/2004 | TheStreet.com

Although 2004 is replete with "blowups" of biotechnology companies, the sector is entering 2005 with good momentum, the most heavily capitalized staying stronger than small-cap firms, according to a senior writer at TheStreet.com. U.S. cutbacks in Medicare reimbursements next year could lead to a trend change in drug usage and affect biotech companies such as Amgen, Genentech and Biogen Idec.

View Full Article in:

TheStreet.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA